Product logins

Find logins to all Clarivate products below.


Acute Respiratory Distress | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017

ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening owing to respiratory failure and/or multi-organ dysfunction. ARDS may be caused by sepsis, trauma, severe pneumonia, or inhalation of harmful substances and it is associated with a high mortality rate. No pharmacological therapy is specifically approved for ARDS and treatment is supportive, principally comprising nonpharmacological approaches (e.g., mechanical ventilation, oxygen supplementation). There is unmet need and thus commercial opportunity for effective pharmacotherapies that can reduce patients’ reliance on ventilation and the mortality associated with ARDS. Apart from Faron Pharmaceuticals/Maruishi Pharmaceuticals’ intravenous interferon beta-1a (Traumakine), the ARDS pipeline comprises largely early- to mid-stage agents with diverse mechanisms of action (e.g., Apeptico/Mediolanum Farmaceutici’s sodium channel modulator solnatide).

QUESTIONS ANSWERED:

How will the size of the ARDS population change through 2026? What are the key drug targets emerging from basic and clinical research in ARDS?

Which emerging therapies do ARDS experts consider most promising? How would new therapies influence management of ARDS patients?

How are emerging ARDS drugs being evaluated, and which are likely to launch by 2026? What commercial impact will they have on the ARDS market?

PRODUCT DESCRIPTION:

Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis, SSc) is a rare, progressive autoimmune disease marked by skin fibrosis, systemic inflammation, and vasculopathy, leading to Raynaud’s phenomenon and painful…
Report
Myasthenia Gravis – Geographic Focus: China – China In-Depth: Myasthenia Gravis
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma – China In-Depth – China
China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…